# 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

> **NCT01626222** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 301 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Exemestane
- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT01626222
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626222, "4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01626222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*